Repurposed asthma drug reverses diabetes in mouse study

02/11/2013 | Genetic Engineering & Biotechnology News

Amlexanox, an off-patent asthma drug, reversed obesity, diabetes and fatty liver disease in mice, according to a study published in Nature Medicine. The drug appears to inhibit the IKK(epsilon) and TBK1 genes, which might allow the metabolic system to burn more energy, University of Michigan Life Sciences Institute researcher Alan Saltiel said. Researchers plan to test the drug in clinical trials and are working on optimized formulas.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA